Positron emission tomographic assessment of 'metabolic flare' to predict response of metastatic breast cancer to antiestrogen therapy

European Journal of Nuclear Medicine

Volumn 26, Issue 1, 1999, Pages 51-56

  Dehdashti, Farrokh ^a   Flanagan, Fidelma L ^a   Mortimer, Joanne E ^b   Katzenellenbogen, John A ^c   Welch, Michael J ^a   Siegel, Barry A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Breast cancer; Estrogen receptor; F1uorine 18 fluorodeoxyglucose; Flare reaction; Positron emission tomography

Indexed keywords

ANTIESTROGEN; ESTROGEN RECEPTOR; FLUORINE 18; FLUORODEOXYGLUCOSE; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HORMONAL THERAPY; HUMAN; METASTASIS; POSITRON EMISSION TOMOGRAPHY; POSTMENOPAUSE; PREDICTION; PROGNOSIS;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; RECEPTORS, ESTROGEN; TAMOXIFEN; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED; TREATMENT OUTCOME;

EID: 0033024916     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050359     Document Type: Article

References (13)

1. 1. Plotkin D, Lechner JJ, Jung WE, et al. Tamoxifen flare in advanced breast cancer. JAMA 1978; 240: 2644-2646.
2. 2. Legha SS: Tamoxifen in the treatment of breast cancer. Ann Intern Med 1988; 109: 219-228.
3. 3. Vogel CL, Schoenfelder J, Shemano I, et al: Worsening bone scan in the evaluation of antitumor response during hormonal therapy of breast cancer. J Clin Oncol 1995; 13: 1123-1128.
4. 4. Mintun MA, Welch MJ, Siegel BA, et al: Breast cancer: PET imaging of estrogen receptors. Radiology 1988; 169: 45-48.
5. 18F]fluoro-17β-estradiol uptake in metastatic breast carcinoma. J Nucl Med 1991; 32: 1526-1531.
6. 6. Dehdashti F, Mortimer JE, Siegel BA, et al: Positron tomographic assessment of estrogen receptors in breast cancer. Comparison with FDG-PET and in vitro receptor assays. J Nucl Med 1995; 36: 1766-1774.
7. 7. Mortimer JE, Dehdashti F, Siegel BA, et al: Clinical correlation of FDG and FES-PET imaging with estrogen receptor and response to systemic therapy. Clin Cancer Res 1996; 2: 933-939.
8. 8. Clark GM, McGuire WL. Progesterone receptors and human breast cancer. Breast Cancer Res Treat 1983; 3: 157-163.
9. 9. Furr BJ, Jordan VC. The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 1984; 25: 127-205.
10. 10. Welch MJ, Bonasera TA, Sherman EIC, et al: [F-18]fluorodeoxyglucose (FDG) and 16α[F-18]fluoroestradiol-17β (FES) uptake in estrogen-receptor (ER)-rich tissues following tamoxifen treatment: a preclinical study [abstract]. J Nucl Med 1995; 36:39P.
11. 11. Wahl RL, Cody R, Fisher S: FDG uptake before and after estrogen receptor stimulation: feasibility studies for functional receptor imaging. [abstract] J Nucl Med 1991; 32: 1011.
12. 12. Buzdar A, Jonat W, Howell A, Jones SE, blomqvist C, Vogel CL, Eirmann W, Wolter J, Azab M, Webster A, Plourde PV of the Arimidex Study Group: Anastrozole, a potent and selective aromatase inhibitor versus megestrolacetate in postmenopauseal women with advanced breast cancer: results of overview analysis of two phase II trials. J Clin Oncol 1996; 14: 2000-2011.
13. 13. Read L, Snider CE, Miller JS, Greene GL, Katzenellenbogen BS. Ligand-modulated regulation of progesterone receptor messenger ribonucleic acid and protein in human breast cancer cell lines. Mol Endocrinol 1988; 2: 263-271.